secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001628280-25-021514
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M
--------------------------------------------------------------------------------

- Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
- IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.
- XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.
- Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.
- Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/0001628280-25-021514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/ardx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-021514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer